Julian Artopé once wore braces and hated them. Years later, that memory of pain and discomfort became the starting point of a company.
He has described the idea in plain terms. Plenty of people want clear aligners. Existing options cost so much that straight teeth had become something of a luxury. In an interview with the South China Morning Post he said exactly that: the demand was there, the price was the wall.
Zenyum 3D-printed transparent aligners, sold them at a flat price, and relied on partner dentists to check and fit them.
There is little public detail on where Artopé grew up or what he studied. What the record does show is speed. He brought in Frederik Krass as co-founder and conceived Zenyum in August 2018. By October, the invisible braces were on sale in Singapore. That is two months from idea to customers, in a field where most dentists measure change in years.
The model was simple to say and hard to run. Zenyum 3D-printed transparent aligners, sold them at a flat price, and relied on partner dentists to check and fit them. The pitch was that a smile should not cost a small fortune. Rivals included Invisalign, with its global brand, and trust was the real hurdle: a patient has to believe that a cheaper aligner will not harm their teeth.
Money followed. A seed of about US$2 million arrived in April 2019, then a US$13.6 million Series A in November 2019 from RTP Global, Sequoia India, TNB Aura and Enterprise Singapore's Seeds Capital. In June 2021, L Catterton led a US$40 million Series B. Total funding is estimated at over US$50 million.
The company did not stay a one-product firm. It added electric toothbrushes, called ZenyumSonic, and a more advanced aligner for complicated cases, ZenyumClear Plus. Data providers now record an acquisition or merger in early 2026, though the buyer and terms are not clear from public listings.
The lesson here is quiet. Artopé did not need a new technology. He needed a customer's grievance, one he had personally lived, and the nerve to ship a product within weeks. A founder who remembers what the pain felt like tends to price the cure differently.